Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02191579 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults

A Phase 4 study of Migraine Disorders, sponsored by Allergan.

Completed
Registry status
Phase 4
Development phase
282
Enrollment target
20
Study locations

NCT02191579 is a Phase 4 study of Migraine Disorders that has completed, run by Allergan. The registered enrollment target is 282 participants, roughly in line with the 302-participant average among 21 other Migraine Disorders trials with a reported enrollment target. The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02191579, a Phase 4 study of Migraine Disorders, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 4
Development phase
282 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the efficacy, safety and tolerability of prophylactic (preventative) treatment with BOTOX® (onabotulinumtoxinA) compared to topiramate in adults with chronic migraine.

Conditions Studied

Migraine Disorders

Interventions

  • DRUG Topiramate
  • BIOLOGICAL onabotulinumtoxinA

Study Locations (20)

Florida

  • Parkinson's Disease and Movement Disorders Center of Boca Raton Inc - Boca Raton
  • Design Neuroscience Center - Doral
  • NW FL Clinical Research Group, LLC - Gulf Breeze
  • Negroski, Sutherland & Hanes Neurology - Sarasota
  • Neurology Research Institute at Palm Beach Neurology - West Palm Beach

California

  • North County Neurology Associates - Encinitas
  • California Headache and Balance Center - Fresno
  • Newport Beach Clinical Research Associates, Inc. - Newport Beach

Kansas

  • International Clinical Research Institute Inc - Overland Park
  • Kansas City Bone and Joint Clinic - Overland Park

Massachusetts

  • MedVadis Research Corporation - Watertown
  • New England Regional Headache Center Inc - Worcester

Missouri

  • Clinvest - Springfield
  • Mercy Health Research - St Louis

Arizona

  • St Joseph's Hospital Barrow Neurology Clinics - Phoenix

Colorado

  • Denver Neurological Clinic - Denver

Connecticut

  • Ki Health Partners LLC DBA New England Institute for Neurology and Headache - Stamford

Trial Details

FieldValue
Enrollment Target 282 participants
Start Date 2014-08-05
Est. Completion 2017-09-01
Phase Phase 4

Sponsor

Allergan

314 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02191579

The ClinicalTrials.gov registry entry for NCT02191579 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 302-participant average among 21 other Migraine Disorders trials with a reported enrollment target. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 2 interventions - of which Topiramate is the first listed.

NCT02191579 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Kansas.

Frequently Asked Questions

What is clinical trial NCT02191579 about?

NCT02191579 is a clinical study titled "Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults". This study will evaluate the efficacy, safety and tolerability of prophylactic (preventative) treatment with BOTOX® (onabotulinumtoxinA) compared to topiramate in adults with chronic migraine.

What is the current status of trial NCT02191579?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 282 participants. The study started on 2014-08-05. Estimated completion is 2017-09-01.

What conditions does trial NCT02191579 study?

This clinical trial studies the following conditions: Migraine Disorders.

What interventions are being tested in trial NCT02191579?

The interventions under investigation include: Topiramate (DRUG), onabotulinumtoxinA (BIOLOGICAL).

Who is sponsoring clinical trial NCT02191579?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02191579 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Migraine Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Migraine Disorders

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.